Caris Life Sciences, Inc. Common Stock (CAI)

Price$16.49

Value ScoreF

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-43.33%

Price vs S&P 500 (4W)2.11%

VGM Score51.10

Market Capitalization$4.66B

All Metrics

P/CF (Annual)56.06x

Book Value / Share (Quarterly)$2.10

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$0.44

Price vs S&P 500 (YTD)-47.04%

Gross Margin (TTM)68.72%

Net Profit Margin (TTM)3.75%

EPS (TTM)$0.11

10-Day Avg Trading Volume2.46M

EPS Excl Extra (TTM)$0.11

EPS (Annual)$-0.41

ROI (Annual)-7.12%

Gross Margin (Annual)66.63%

Cash / Share (Quarterly)$2.91

P/E Basic Excl Extra (TTM)137.17x

Revenue Growth QoQ (YoY)78.78%

ROA (Last FY)-6.05%

EBITD / Share (TTM)$0.38

Operating Margin (TTM)9.75%

Cash Flow / Share (Annual)$0.24

P/B Ratio7.85x

P/B Ratio (Quarterly)8.52x

Net Income / Employee (Annual)$-36,900

EV / Revenue (TTM)4.65x

Net Interest Coverage (TTM)0.27x

ROA (TTM)3.22%

EV / EBITDA (TTM)38.70x

EPS Incl Extra (Annual)$-0.41

Current Ratio (Annual)7.85x

Quick Ratio (Quarterly)6.38x

3-Month Avg Trading Volume2.58M

EV / Free Cash Flow (Annual)63.11x

P/E Incl Extra (TTM)137.17x

Revenue / Employee (TTM)$491,500

P/S Ratio (Annual)5.74x

Asset Turnover (Annual)0.72x

52-Week High$42.50

EPS Excl Extra (Annual)$-0.41

26-Week Price Return-35.41%

Quick Ratio (Annual)7.19x

13-Week Price Return-14.20%

Total Debt / Equity (Annual)0.66x

Current Ratio (Quarterly)7.05x

Enterprise Value$4.22B

Asset Turnover (TTM)0.86x

Revenue / Employee (Annual)$439,900

Pretax Margin (Annual)-8.38%

Cash / Share (Annual)$2.83

3-Month Return Std Dev76.55%

Net Income / Employee (TTM)$18,400

ROE (Last FY)-11.79%

Net Interest Coverage (Annual)1.63x

EPS Basic Excl Extra (Annual)$-0.41

P/FCF (TTM)37.76x

Receivables Turnover (TTM)10.63x

EV / Free Cash Flow (TTM)34.20x

Total Debt / Equity (Quarterly)0.64x

EPS Incl Extra (TTM)$0.11

ROI (TTM)3.76%

P/S Ratio (TTM)5.14x

Revenue / Share (Annual)$4.86

Forward P/E71.12x

P/E Ratio (TTM)137.17x

Year-to-Date Return-38.88%

5-Day Price Return0.24%

EPS Normalized (Annual)$-0.41

Net Profit Margin (Annual)-8.38%

Month-to-Date Return-1.38%

EBITD / Share (Annual)$0.15

Operating Margin (Annual)3.11%

LT Debt / Equity (Annual)0.66x

P/CF (TTM)31.63x

P/E Excl Extra (TTM)137.17x

LT Debt / Equity (Quarterly)0.64x

EPS Basic Excl Extra (TTM)$0.11

P/B Ratio (Annual)13.19x

Inventory Turnover (TTM)5.03x

Pretax Margin (TTM)3.73%

Book Value / Share (Annual)$2.04

Price vs S&P 500 (13W)-22.46%

Beta0.27x

P/FCF (Annual)69.68x

Revenue / Share (TTM)$3.21

ROE (TTM)6.47%

52-Week Low$14.19

vGradeF

gGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.00est. -0.02

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.23

4.29

4.24

Industry Peers — Health Services(28)

Symbol	Value Score	Growth Score	Momentum Score	Price
CAICaris Life Sciences, Inc. Common Stock	F	A	D	$16.49
NTRANatera, Inc. Common Stock	F	A	C	$215.31
DGXQuest Diagnostics Inc.	C	D	C	$200.29
LHLabcorp Holdings Inc.	C	D	C	$265.15
EXASExact Sciences Corp	F	B	B	$0.00
GHGuardant Health, Inc. Common Stock	F	A	B	$125.61
CELCCelcuity Inc. Common Stock	—	—	C	$88.28
RDNTRadNet, Inc. Common Stock	D	C	C	$54.34
VCYTVeracyte, Inc.	D	A	B	$48.73
GRALGRAIL, Inc. Common Stock	D	A	C	$59.98
FTREFortrea Holdings Inc. Common Stock	B	F	A	$16.08

About

Caris Life Sciences develops AI-powered molecular diagnostic solutions for oncology, enabling personalized cancer treatment decisions. The company leverages comprehensive molecular profiling and machine learning algorithms to provide physicians with precision medicine insights. Its technology platform aims to improve patient outcomes while supporting clinical and pharmaceutical decision-making.